NVX-CoV2373
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04889209 | May 2021 → Jun 2023 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/2 | NCT04712110 | Feb 2021 → Mar 2022 | COVID-19 | Takeda | Completed | No outcome recorded |
| Phase 1/2 | NCT04368988 | May 2020 → Jun 2022 | COVID-19 | Novavax | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06027229 | Nov 2023 → Apr 2024 | COVID-19, immunodeficiency disease | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 2 | NCT05112848 | Feb → May 2022 | COVID-19 | Novavax | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05925127 | Oct 2023 → May 2024 | COVID-19 | Novavax | Completed | No outcome recorded |
| Phase 2/3 | NCT05468736 | Jul 2022 → Jan 2024 | COVID-19 | Novavax | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT05875701 | Mar → Nov 2023 | COVID-19 | Novavax | Completed | No outcome recorded |
| Phase 3 | NCT05463068 | Jul → Aug 2022 | COVID-19 | Novavax | Completed | No outcome recorded |
| Phase 3 | NCT05372588 | May → Jul 2022 | COVID-19 | Novavax | Completed | No outcome recorded |
| Phase 3 | NCT05299359 | Apr → Jun 2022 | COVID-19 | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT05249816 | Mar 2022 → May 2023 | COVID-19 | Cogna Technology Solutions LLC | Completed | No outcome recorded |
| Phase 3 | NCT04611802 | Dec 2020 → Apr 2023 | COVID-19 | Novavax | Completed | No outcome recorded |
| Phase 3 | NCT04583995 | Sep 2020 → Mar 2022 | COVID-19 | Novavax | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05775887 Comparator | May → Dec 2023 | COVID-19 | The University of Queensland | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05973006 Comparator | Aug 2023 → Apr 2024 | COVID-19 | Novavax | Completed | No outcome recorded |
| Phase 3 | NCT05658523 Comparator | Feb 2023 → Oct 2024 overdue | COVID-19 | Murdoch Childrens Research Institute | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-04-19 | Takeda | Takeda Announces Approval of Nuvaxovid ® COVID-19 Vaccine for Primary and Booster Immunization in Japan takeda.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NVX CoV2373 | “Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine:...” PMID 37198021 ↗ May 202317“Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised,...” PMID 34800364 ↗ Nov 2021 “Group 15E - previously EUA-dosed vaccination with Janssen (two doses for Group 15E) - Ad26.COV2.S at 5x1010 vp followed by a dose of NVX-CoV2373 (5 mcg Prototype SARS-CoV-2 rS...” NCT04889209 ↗ “NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins...” PMID 32877576 ↗ Sep 2020 “Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.” PMID 35501178 ↗ Apr 2022 “and NVX CoV2373 or a variant-based vaccine given as a booster dose or at crossover in pediatric participants” NCT05468736 ↗ “A site-mixed bivalent vaccine prepared by combining 0.25 mL of NVX-CoV2373 and 0.25 mL NVX-CoV2601.” NCT05973006 ↗ “2 primary doses of SARS-CoV-2 rS with Matrix-M™ adjuvant (NVX-CoV2373) given 21 days apart” NCT05468736 ↗ “NVX-CoV2373 is an adjuvanted, recombinant spike protein nanoparticle vaccine” PMID 34910859 ↗ Dec 2021 “including NVX-CoV2373 (an adjuvanted recombinant protein vaccine).” PMID 37652823 ↗ Aug 2023 “Drug: NVX-Cov2373” NCT05372588 ↗ |
| Known as | Novavax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05658523 ↗ |
| Known as | Nuvaxovid | “a single booster dose of either UQSC2 or the approved comparator NVX-CoV2373 (Nuvaxovid; Novavax)” PMID 41285172 ↗ Feb 2026 |
| Known as | NVX-CoV2372 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06027229 ↗ |
| Known as | TAK-019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04712110 ↗ |
| Modality | Vaccine | “NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine” PMID 32877576 ↗ Sep 2020 |
| Route | Intramuscular | “Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21.” NCT04583995 ↗ |